{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:46:02Z","timestamp":1790891162760,"version":"4.1.0"},"reference-count":26,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2013,10,22]],"date-time":"2013-10-22T00:00:00Z","timestamp":1382400000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2014,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>In standard regimens for <jats:italic>Helicobacter pylori<\/jats:italic> infection, amoxicillin is dosed twice daily, although the bactericidal effect of amoxicillin depends on the %time\u2010above\u2010MIC. We aimed to examine whether dosing schemes of amoxicillin influenced eradication rates of amoxicillin\u2010based regimens.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>One hundred eighty\u2010seven patients infected with clarithromycin\u2010sensitive strains of <jats:italic>H. pylori<\/jats:italic> were treated with PPI, clarithromycin 200 mg bid and amoxicillin 750\u2009mg bid, 500\u2009mg tid or 500\u2009mg qid for 1 week and 125 infected with clarithromycin\u2010resistant strains were treated with PPI, metronidazole 250\u2009mg bid and amoxicillin 750\u2009mg bid, 500\u2009mg tid or 500\u2009mg qid for 1 week.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Eradication rates (ITT) of the triple PPI\/amoxicillin\/clarithromycin therapy with bid, tid and qid dosings of amoxicillin were 77.8% (49\/63), 93.5% (58\/62), and 91.9% (57\/62), respectively. Those of the triple PPI\/amoxicillin\/metronidazole therapy were 80.5% (33\/41), 90.5% (38\/42), and 95.2% (40\/42), respectively. Eradication rates in regimens with tid and qid dosing of amoxicillin were higher than those of regimens with the bid dosing of amoxicillin.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The dosing scheme of amoxicillin significantly influenced eradication rates of triple therapies. Although amoxicillin is empirically dosed twice daily, amoxicillin should be dosed at least three times daily in amoxicillin\u2010based triple therapies.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jcph.195","type":"journal-article","created":{"date-parts":[[2013,10,12]],"date-time":"2013-10-12T02:13:14Z","timestamp":1381543994000},"page":"258-266","source":"Crossref","is-referenced-by-count":52,"title":["Effect of dosing schemes of amoxicillin on eradication rates of <i>Helicobacter pylori<\/i> with amoxicillin\u2010based triple therapy"],"prefix":"10.1002","volume":"54","author":[{"given":"Takahisa","family":"Furuta","sequence":"first","affiliation":[{"name":"Center for Clinical Research Hamamatsu University School of Medicine Hamamatsu Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsushige","family":"Sugimoto","sequence":"additional","affiliation":[{"name":"First Department of Medicine Hamamatsu University School of Medicine Hamamatsu Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihoko","family":"Yamade","sequence":"additional","affiliation":[{"name":"First Department of Medicine Hamamatsu University School of Medicine Hamamatsu Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Uotani","sequence":"additional","affiliation":[{"name":"First Department of Medicine Hamamatsu University School of Medicine Hamamatsu Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Sahara","sequence":"additional","affiliation":[{"name":"First Department of Medicine Hamamatsu University School of Medicine Hamamatsu Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Ichikawa","sequence":"additional","affiliation":[{"name":"First Department of Medicine Hamamatsu University School of Medicine Hamamatsu Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Yamada","sequence":"additional","affiliation":[{"name":"First Department of Medicine Hamamatsu University School of Medicine Hamamatsu Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Osawa","sequence":"additional","affiliation":[{"name":"First Department of Medicine Hamamatsu University School of Medicine Hamamatsu Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Sugimoto","sequence":"additional","affiliation":[{"name":"First Department of Medicine Hamamatsu University School of Medicine Hamamatsu Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Center for Clinical Research Hamamatsu University School of Medicine Hamamatsu Japan"},{"name":"Department of Clinical Pharmacology and Therapeutics Hamamatsu University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Umemura","sequence":"additional","affiliation":[{"name":"Center for Clinical Research Hamamatsu University School of Medicine Hamamatsu Japan"},{"name":"Department of Pharmacology Hamamatsu University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,10,22]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2009.05982.x"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2002.01368.x"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkf172"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200038030-00004"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5520(03)00065-5"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1470-9465.2004.00865.x"},{"key":"e_1_2_9_8_1","first-page":"1314","article-title":"The dual therapy with 4 times daily dosing of rabeprazole and amoxicillin as the 3rd rescue regimen for eradication of H. pylori","volume":"57","author":"Furuta T","year":"2010","journal-title":"Hepatogastroenterology."},{"key":"e_1_2_9_9_1","first-page":"2274","article-title":"High\u2010dose rabeprazole\/amoxicillin therapy as the second\u2010line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin","volume":"50","author":"Furuta T","year":"2003","journal-title":"Hepatogastroenterology."},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-5378.2003.00158.x"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01659.x"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100043"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/40.2.283"},{"key":"e_1_2_9_14_1","first-page":"36","article-title":"Clinical studies of 13C\u2010urea breath test in Japan","volume":"33","author":"Kato M","year":"1998","journal-title":"J Gastroenterol."},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2010.08.007"},{"key":"e_1_2_9_16_1","first-page":"272","article-title":"Post\u2010antibiotic effect of three quinolones against gram negative isolates from urine","volume":"47","author":"Alados JC","year":"1990","journal-title":"Med Lab Sci."},{"key":"e_1_2_9_17_1","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1128\/AAC.41.10.2218","article-title":"Pharmacodynamic effects of antibiotics and acid pump inhibitors on Helicobacter pylori","volume":"41","author":"Sorberg M","year":"1997","journal-title":"Antimicrob Agents Chemother."},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/42.5.661"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2001.113959"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200106000-00009"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-007-0302-8"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-010-0220-x"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2008.05408.x"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01401.x"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-5378.2001.00037.x"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2007.03057.x"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2009.03578.x"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcph.195","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.195","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T15:45:25Z","timestamp":1696347925000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,22]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["10.1002\/jcph.195"],"URL":"https:\/\/doi.org\/10.1002\/jcph.195","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,22]]}}}